EP1480628A1 - Utilisation d'inhibiteurs du transporteur de ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires - Google Patents

Utilisation d'inhibiteurs du transporteur de ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires

Info

Publication number
EP1480628A1
EP1480628A1 EP03706415A EP03706415A EP1480628A1 EP 1480628 A1 EP1480628 A1 EP 1480628A1 EP 03706415 A EP03706415 A EP 03706415A EP 03706415 A EP03706415 A EP 03706415A EP 1480628 A1 EP1480628 A1 EP 1480628A1
Authority
EP
European Patent Office
Prior art keywords
vwf
use according
inhibitors
treatment
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03706415A
Other languages
German (de)
English (en)
Inventor
Hans-Jochen Lang
Stefan Werner Schneider
Hans Oberleithner
André NIEMEYER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of EP1480628A1 publication Critical patent/EP1480628A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the invention relates to the use of inhibitors of the cellular sodium-hydrogen exchanger in human and veterinary medicine for the prevention and treatment of acute or chronic diseases which are caused by elevated blood levels of the von Willebrand factor.
  • the inhibitors can therefore be used to treat thrombotic and inflammatory diseases.
  • NHE sodium hydrogen exchanger
  • the important mechanism of action of the NHE inhibitors in acute ischemia is that they reduce the increased sodium ion influx which arises in acutely deficient tissue through activation of the NHE due to intracellular acidification. This will make the situation of sodium overload of the tissue . delayed. Since sodium and calcium ion transport are coupled to each other in the heart tissue, this prevents the life-threatening calcium overload of the heart cells.
  • the inhibitors of the NHE bring about protection of the central nervous system (CNS), such active substances protecting the CNS, similar to the heart, against acute ischemic conditions. These conditions are caused by an acute lack of blood circulation and thus by an Lack of supply with nutrients, oxygen or minerals. Such ischemic damage to the CNS is particularly pronounced in central infarcts, such as a stroke. With normal, healthy blood flow, therefore, as expected, no protective effects of NHE inhibitors were also possible. against these acute events, since no acute ischemic tissue damage to the heart or the CNS occurred.
  • CNS central nervous system
  • platelet aggregation inhibitors such as acetylsalicylic acid, dipyridamole and ticlopidine
  • anticoagulants such as heparins or heparinoids.
  • the blood coagulation cascade can be mechanistically divided into two paths, as shown in the following scheme, namely an intrinsic and an extrinsic course, both of which ultimately result in the activation of factor X and the resulting generation of thrombin and subsequently fibrin:
  • a disadvantage of the known therapeutic agents on the market that intervene in the coagulation process as inhibitors is therefore the high risk of bleeding complications.
  • high dose thrombolysis therapy e.g. B. as part of the therapy of acute myocardial infarction or pulmonary embolism, there is a risk of life-threatening bleeding. Therefore there is an urgent one Need for therapeutic agents that, despite overdosing, carry no risk of increased bleeding tendency.
  • vWF von Willebrand factor
  • vWF von Willebrand factor
  • factor VIII factor VIII bound by vWF
  • antithrombotic agents that antagonize the stabilizing binding of the vWF to factor VIII can also be disadvantageous because in the event of an overdose, extensive inhibition of blood coagulation and dangerous bleeding tendencies must be expected.
  • the compounds used according to the invention inhibit the release of the von Willebrand factor from the endothelial cells.
  • the compounds according to the invention inhibit the massive pH-dependent release of the vWF accumulated in ischemia.
  • the transmembrane protein P-selectin is also stored in the Weibel-Palade bodies (Wagner, DD 1993, Thromb. Haemost, 70: 105-110).
  • the P-selectin is located in the vesicle membrane and is after the vesicle fusion (exocytosis ) built into the plasma membrane of the endothelial cell. Every Weibel-Palade body exocytosis thus leads not only to an increased release of vWF, but also to an increased P-selectin expression in the endothelial cell membrane.
  • vWF secretion (quantitative measurement by means of ELISA) is shown under acidosis, as well as during a subsequent reperfusion. In parallel, these quantitative measurements are made with Immunofluorescence data from the Weibel-Palade bodies confirmed.
  • the measured vWF is not only a marker for increased (increase in WF secretion) or decreased (decrease in vWF secretion) tendency to thrombosis (via the increase in aggregation of the platelets), but also a direct marker for an increased or decreased P-selectin expression in the endothelial cell membrane.
  • P-selectin serves as an anchor for leukocytes and thus the initial inflammatory reaction (Vestweber, D., Blanks, JE 1999, Physiol. Rev., 79: 181-213; Issekutz, AC, Issekutz, TB 2002, J. Immunol., 168 : 1934 to 1939).
  • the pathophysiological significance is diverse and is evidence of ischemia / reperfusion disorders, thrombosis and arteriosclerosis (Massberg, S., et al., 1998, Blood, 92: 507-515;
  • P-selectin As an inflammation marker and initiator of inflammation, it plays an essential role in the process of cancer spreading (Varki, A., Varki, NM 2001, Braz. J. Med. Biol. Res. 34: 711-717) , as well as during different joint inflammations (arthritis) (Veihelmann, A. et al, 1999, Microcirculation, 6: 281-290; Mclnnes, LB., et al., 2001, J. Immunol., 167: 4075-4082).
  • the mode of action of the substances described here can therefore also be used as a therapeutic agent for all of the above-mentioned P-selectin-associated diseases.
  • the invention therefore relates to the use of inhibitors of sodium
  • Hydrogen exchanger for the manufacture of medicines for the prophylaxis and therapy of acute or chronic diseases caused by elevated blood levels of the von Willebrand factor.
  • the invention further relates to the use of at least one of the following compounds
  • Another object of the invention is the use of cariporides
  • the separation into the pure stereoisomers is possible either by chromatography on an optionally chiral support material or, if the racemic compounds mentioned above are capable of salt formation, by fractional crystallization the diastereomeric salts formed with an optically active base or acid as auxiliary.
  • Modified silica supports so-called Pirkle phases
  • high-molecular carbohydrates such as triacetyl cellulose are suitable as chiral stationary phases for the separation of enantiomers by thin-layer or column chromatography.
  • the optically active, usually commercially available base such as (-) - nicotine, (+) - and (-) - phenylethylamine, quinine bases, L-lysine or L- and D-arginine are used to dissolve the differently soluble diastereomeric salts formed, the less soluble component isolated as a solid, the more soluble diastereomer separated from the mother liquor, and the pure enantiomers obtained from the diastereomeric salts thus obtained.
  • racemic compounds of the formula I which contain a basic group such as an amino group
  • optically active acids such as (+) - camphor-10-suifonic acid, D- and L-tartaric acid, D- and L- Convert lactic acid and (+) and (-) - mandelic acid into the pure enantiomers.
  • chiral compounds which contain alcohol or amine functions with correspondingly activated or optionally N-protected enantiomerically pure amino acids in the corresponding esters or amides, or conversely chiral carboxylic acids with carboxy-protected enantiomerically pure amino acids in the amides or with enantiomerically pure hydroxycarboxylic acids such as lactic acid transfer the corresponding chiral ester.
  • the chirality of the amino acid or alcohol residue introduced in enantiomerically pure form can be used to separate the isomers by separating the diastereomers now present by crystallization or chromatography on suitable stationary phases and then cleaving off the chiral part of the molecule carried along using suitable methods.
  • Acidic or basic products of the above-mentioned compounds can be in the form of their salts or in free form.
  • the production of physiologically compatible salts from the abovementioned compounds capable of salt formation, including their stereoisomeric forms, is carried out in a manner known per se.
  • the carboxylic acids and hydroxamic acids form with alkaline reagents such as hydroxides, carbonates, hydrogen carbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or also basic amino acids, such as lysine, ornithine or arginine, stable alkali metal, alkaline earth metal or, if appropriate substituted ammonium salts. If the above-mentioned compounds have basic groups, stable acid addition salts can also be prepared with strong acids.
  • alkaline reagents such as hydroxides, carbonates, hydrogen carbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine or triethanolamine or also basic amino acids, such as lysine, ornithine or arginine, stable alkali metal, alkaline earth metal or, if appropriate substituted ammonium salts. If the above-mentioned compounds have basic groups, stable acid addition salt
  • Both inorganic and organic acids such as hydrogen chloride, hydrogen bromide, sulfur, phosphorus, methanesulfone, benzenesulfone, p-toluenesulfone, 4-bromobenzene sulfone, cyclohexylamidosulfone, trifluoromethylsulfone, vinegar and oxal come for this -, Tartaric, succinic or trifluoroacetic acid in question.
  • Methanesulfonic acid salts of the abovementioned compounds are particularly preferred.
  • the above-mentioned compounds are suitable for the prophylaxis and therapy of acute or chronic diseases which are caused by increased blood levels of the von Willebrand factor and / or increased expression of the P-selectin.
  • thrombotic diseases that are provoked by ischemic conditions with subsequent reperfusion; such as thrombosis in acute myocardial, mesenteric or even cerebral infarction; thrombotic diseases that occur during or after surgery; pulmonary emboli; deep venous thrombotic diseases that are provoked by ischemic conditions with subsequent reperfusion; such as thrombosis in acute myocardial, mesenteric or even cerebral infarction; thrombotic diseases that occur during or after surgery; pulmonary emboli; deep venous thrombotic diseases that are provoked by ischemic conditions with subsequent reperfusion; such as thrombosis in acute myocardial, mesenteric or even cerebral infarction; thrombotic diseases that occur during or after surgery; pulmonary emboli; deep venous thrombotic diseases that occur during or after surgery; pulmonary emboli; deep venous thrombotic diseases that are provoked by ischemic conditions with subsequent reperfusion; such as thrombosis in acute myocardial, me
  • Thromboses such as those that occur after a prolonged restriction of the blood circulation, in particular of the lower extremities, for example after lying or sitting for a long time, and inflammatory diseases, such as those during ischemia and subsequent reperfusion, during vasculitis (e.g. as part of an autoimmune disease or collagenosis) , occur.
  • the medicaments according to the invention can be administered by oral, inhalative, rectal or transdermal application or by subcutaneous, intra-articular, intraperitoneal or intravenous injection. Oral application is preferred.
  • the invention also relates to a method for producing a medicament, which is characterized in that at least one of the above
  • the above-mentioned compounds are mixed with the suitable additives such as carriers, stabilizers or inert diluents and brought into suitable dosage forms by the customary methods, such as tablets, dragées, push-fit capsules, aqueous, alcoholic or oily suspensions or aqueous or oily solutions.
  • suitable additives such as carriers, stabilizers or inert diluents and brought into suitable dosage forms by the customary methods, such as tablets, dragées, push-fit capsules, aqueous, alcoholic or oily suspensions or aqueous or oily solutions.
  • inert carriers such.
  • the preparation can take place both as dry and as moist granules.
  • Vegetable or animal oils such as sunflower oil or cod liver oil, are suitable as oily carriers or solvents.
  • the active compounds are, if desired, brought into solution, suspension or emulsion with the suitable substances, such as solubilizers, emulsifiers or other auxiliaries.
  • suitable substances such as solubilizers, emulsifiers or other auxiliaries.
  • solvents such.
  • physiological saline or alcohols e.g. As ethanol, propanol, glycerin, in addition
  • Sugar solutions such as glucose or mannitol solutions, or a mixture of the various solvents mentioned.
  • customary auxiliaries such as carriers, disintegrants, binders, coatings, swelling agents, lubricants or lubricants, flavorings, sweeteners and solubilizers, are used.
  • Magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, cellulose and its derivatives, animal and vegetable oils such as cod liver oil, sunflower, peanut or sesame oil, polyethylene glycol and solvents such as sterile are common additives Water and monohydric or polyhydric alcohols such as glycerin.
  • the above-mentioned compounds are preferably prepared and administered as pharmaceutical preparations in dosage units, each unit containing as active ingredient a certain dose of the compound of the formula I.
  • the dosage can also be increased in severe cases. In many cases, however, lower doses are sufficient.
  • These figures refer to an adult weighing approximately 75 kg.
  • the above-mentioned compounds can be used alone or in combination with anticoagulant, platelet aggregation-inhibiting or fibrinolytic active substances.
  • the co-application can take place, for example, with factor Xa inhibitors, standard heparin, low molecular weight heparins such as enoxaparin, dalteparin, certroparin, parnaparin or tinzaparin, direct thrombin inhibitors such as hirudin, aspirin, fibrinogen receptor antagonists, streptokinase, urokinase and / or activator plasmin and / or activator plasmin ,
  • Example 1 the cells were cultured either on gelatinized glass plates (measurement of the intracellular proton concentration) or on cell culture plates (12-well culture plates, Falcon, New Jersey, USA; measurement of the vWF release) after the first passage.
  • Example 1 the cells were cultured either on gelatinized glass plates (measurement of the intracellular proton concentration) or on cell culture plates (12-well culture plates, Falcon, New Jersey, USA; measurement of the vWF release) after the first passage.
  • gelatinized glass plates measurement of the intracellular proton concentration
  • cell culture plates (12-well culture plates, Falcon, New Jersey, USA; measurement of the vWF release
  • HUVECs were loaded with the pH-sensitive fluorescent dye BCECF-AM (2 ', 7'-bis (carboxyethyl) - 5 (6) -carboxyfluorescein).
  • BCECF-AM 2 ', 7'-bis (carboxyethyl) - 5 (6) -carboxyfluorescein.
  • a Deltascan Spectrofluorometer (PTI, Hamburg) was used for the subsequent measurement of the fluorescence.
  • This measuring system essentially consists of a UV light source, a monochromator, a photon detector and the software packages Felix and Oscar (PTI, Hamburg) for controlling the system via a computer.
  • the ratio of the measured emissions of the BCECF was recorded and the pH value was determined after calibration.
  • the measuring chamber is constructed in such a way that the parameters of temperature and the carbon dioxide partial pressure of the system are checked with continuous perfusion. For the reperfusion simulation, the test conditions were set to 37 ° C. and a carbon dioxide partial pressure of 5% or 10% by gassing the system and perfusate.
  • Reperfusion buffer of the NHE inhibitor cariporide was added in a concentration of 10 ⁇ M.
  • Table 1 Intracellular pH during an extracellular acidosis (pHj (acidosis)) of at least 15 minutes or under control conditions (Co).
  • SEM is the standard deviation from the mean
  • Extracellular acidosis resulted in intracellular acidification that persisted throughout the duration of the acidosis.
  • the cells mentioned were first washed with acidic medium (pH 6.4 from the components: medium M199 w / Earle 's & Amino Acids, w / L-glutamine, w / o NaHCO 3 , w / o Hepes + 0.084 g NaHCO 3 / 1) or pH standard medium (pH 7.4 from the constituents: medium M199 w / Earle's & amino Acids, w / L-glutamine, w / o NaHCO3, w / o Hepes + 2,200g NaHCO 3/1) incubated for one, three or 48 hours.
  • acidic medium pH 6.4 from the components: medium M199 w / Earle 's & Amino Acids, w / L-glutamine, w / o NaHCO 3 , w / o Hepes + 0.084 g NaHCO 3 /
  • pH standard medium pH standard medium
  • vWF content of Standard Human Plasma (Behring, Marburg) is based on an international Standards (2 nd International Standard 87/718; National Institute for Biological
  • the vWF concentration under control conditions is set to 100%.
  • vWF secretion was measured during a 10 minute reperfusion period with stimulation.
  • the vWF secretion of the control cells (vWF c0 ) was set to 100%.
  • the vWF concentration during reperfusion of preacidotic cells (vWFacidosis) and the vWF concentration during reperfusion of preacidotic cells in the presence of 10 ⁇ M cariporide (VWFH O E) were given as relative values to the control values. Control cells were incubated with Cariporide

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Des inhibiteurs de l'antiporteur ions sodium-hydrogène cellulaire ont un effet inhibiteur sur la sécrétion du facteur von Willebrand et/ou sur l'expression élevée de la P-selectine. Ces inhibiteurs peuvent donc être utilisés pour le traitement de maladies thrombotiques et inflammatoires.
EP03706415A 2002-02-14 2003-02-03 Utilisation d'inhibiteurs du transporteur de ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires Withdrawn EP1480628A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10206358A DE10206358A1 (de) 2002-02-14 2002-02-14 Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Behandlung von thrombotischer und inflammatorischer Erkrankungen
DE10206358 2002-02-14
PCT/EP2003/001020 WO2003068212A1 (fr) 2002-02-14 2003-02-03 Utilisation d'inhibiteurs de l'antiporteur ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires

Publications (1)

Publication Number Publication Date
EP1480628A1 true EP1480628A1 (fr) 2004-12-01

Family

ID=27634998

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03706415A Withdrawn EP1480628A1 (fr) 2002-02-14 2003-02-03 Utilisation d'inhibiteurs du transporteur de ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires

Country Status (10)

Country Link
EP (1) EP1480628A1 (fr)
JP (1) JP2005525336A (fr)
AR (1) AR038502A1 (fr)
AU (1) AU2003208368A1 (fr)
BR (1) BR0307618A (fr)
CA (1) CA2476446A1 (fr)
DE (1) DE10206358A1 (fr)
MX (1) MXPA04007387A (fr)
TW (1) TW200403988A (fr)
WO (1) WO2003068212A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10305070A1 (de) * 2003-02-07 2004-08-26 Merck Patent Gmbh Verwendung von N-(4,5-Methansulfonyl-2-methyl-benzoyl)-guanidin
AU2009243749B2 (en) * 2008-05-09 2013-11-21 Merck Patent Gmbh Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627193A (en) * 1995-02-09 1997-05-06 Mitsui Toatsu Chemicals, Inc. Quinoline-4-carbonylguanidine derivatives, process for producing the same and pharmaceutical preparations containing the compounds
DE19734693A1 (de) * 1997-08-11 1998-01-22 Hoechst Marion Roussel De Gmbh Verwendung von Cariporide als Inhibitor des zellulären NA+/H+-Exchangers (NHE) zur Herstellung eines Medikaments zur Behandlung von cardialen und nichtcardialen Krankheiten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03068212A1 *

Also Published As

Publication number Publication date
CA2476446A1 (fr) 2003-08-21
AU2003208368A1 (en) 2003-09-04
DE10206358A1 (de) 2003-08-28
TW200403988A (en) 2004-03-16
AR038502A1 (es) 2005-01-19
BR0307618A (pt) 2004-12-21
JP2005525336A (ja) 2005-08-25
WO2003068212A1 (fr) 2003-08-21
MXPA04007387A (es) 2004-10-11

Similar Documents

Publication Publication Date Title
DE69926750T2 (de) Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten
DE3606892A1 (de) Pharmazeutische formulierungen und verfahren zur behandlung von gedaechtnisstoerungen
DD211351A5 (de) Verfahren zur herstellung von neuen thieno-(3,2-c)pyridin-derivaten
DE60032905T2 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE102006056766A1 (de) Verwendung von kompatiblen Soluten
DE19842415A1 (de) Pharmazeutische Zubereitung
DE10201550A1 (de) Phenoxy-Piperidine
EP1067965B1 (fr) Composition pharmaceutique pour traiter l'apoplexie cerebrale et le traumatisme craniocerebral
US5023244A (en) Anti-dementia agents
DE69911633T2 (de) Pharmazeutische zusammenstellungen die tetrahydroisoquinoleinverbindungen enthalten
DE19634313A1 (de) Methode zur Stabilisierung von Plättchen
DE2846251A1 (de) Guanidinbenzoesaeureverbindungen, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
DE69736130T2 (de) Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen
DE60316297T2 (de) Verbindungen, die zur behandlung von erkrankungen, die auf antiangiogene therapie ansprechen, nützlich sind
EP0312913B2 (fr) Usage des paf-antagonistes pour la préparation d'un medicament et méthode pour la détermination de leur activité bloquante
FI105025B (fi) Menetelmä valmistaa (S)-alfa-fenyyli-2-pyridiinietaaniamiinia
EP2190430A1 (fr) Utilisation de composés dérivés du cycloheximide pour le traitement ou la prévention en particulier d'ischémies et de maladies cardiaques
EP1480628A1 (fr) Utilisation d'inhibiteurs du transporteur de ions sodium-hydrogene pour le traitement de maladies thrombotiques et inflammatoires
US20040192699A1 (en) Optic nerve protecting agents containing alpha1 receptor blocker as active ingredient
WO2003068224A2 (fr) Utilisation d'inhibiteurs de l'echangeur chlorure-bicarbonate sodium-dependant pour traiter des affections thrombotiques et inflammatoires
US20030220383A1 (en) Use of inhibitors of the sodium-dependent chloride/bicarbonate exchanger for the treatment of thrombotic and inflammatory disorders
EP0206297B1 (fr) Amino-4(imidazolidinone-2 yl-1)-2N-(trifluorométhyl-3 phényl)pyrimidinecarboxamides-5 utiles pour la prophylaxie et le traitement antithrombotique ainsi que leur utilisation pour la préparation de médicaments antithrombotiques
DE2328896A1 (de) Quaternaere phenylcycloalkylammoniumverbindungen und daraus hergestellte arzneipraeparate
WO2000032199A1 (fr) Utilisation de galanthamine et de derives de galanthamine en cas de lesions cerebrales fonctionnelles aigues
US20040097583A1 (en) Use of inhibitors of the sodium/hydrogen exchanger for the treatment of thrombotic and inflammatory disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040914

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20060622